ITF-2984 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses ITF-2984 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses ITF-2984 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Phase II Study With ITF2984 in Acromegalic PatientsCompletedPhase 2ItalfarmacoNCT02111044Written as ITF2984 500 mcg
- A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy VolunteersCompletedPhase 1ItalfarmacoNCT01897844Written as ITF2984 (100, 2000, 3000 mcg bid)
- ITF2984 Repeated Doses Study in Healthy VolunteersCompletedPhase 1ItalfarmacoNCT01871844Written as ITF2984 (500, 1000, 2000 mcg bid for 7 days)